BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 36285515)

  • 1. Nivolumab-induced radiation recall pneumonitis in non-small-cell lung cancer patients with thoracic radiation therapy.
    Noda-Narita S; Naito T; Udagawa H; Goto K; Miyawaki T; Mamesaya N; Nakashima K; Kenmotsu H; Shimokawaji T; Kato T; Hakozaki T; Okuma Y; Nakamura M; Nakayama Y; Watanabe H; Kusumoto M; Ohe Y; Horinouchi H
    Cancer Sci; 2023 Feb; 114(2):630-639. PubMed ID: 36285515
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comprehensive Pneumonitis Profile of Thoracic Radiotherapy Followed by Immune Checkpoint Inhibitor and Risk Factors for Radiation Recall Pneumonitis in Lung Cancer.
    Lu X; Wang J; Zhang T; Zhou Z; Deng L; Wang X; Wang W; Liu W; Tang W; Wang Z; Wang J; Jiang W; Bi N; Wang L
    Front Immunol; 2022; 13():918787. PubMed ID: 35795657
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Radiation recall pneumonitis induced by chemotherapy after thoracic radiotherapy for lung cancer.
    Ding X; Ji W; Li J; Zhang X; Wang L
    Radiat Oncol; 2011 Mar; 6():24. PubMed ID: 21375774
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Incidence, risk factors, and CT characteristics of radiation recall pneumonitis induced by immune checkpoint inhibitor in lung cancer.
    Cousin F; Desir C; Ben Mustapha S; Mievis C; Coucke P; Hustinx R
    Radiother Oncol; 2021 Apr; 157():47-55. PubMed ID: 33453313
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High incidence and early onset of nivolumab-induced pneumonitis: four case reports and literature review.
    Koyama N; Iwase O; Nakashima E; Kishida K; Kondo T; Watanabe Y; Takahashi H; Umebayashi Y; Ogawa Y; Miura H
    BMC Pulm Med; 2018 Jan; 18(1):23. PubMed ID: 29378571
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Decreased risk of radiation pneumonitis with incidental concurrent use of angiotensin-converting enzyme inhibitors and thoracic radiation therapy.
    Kharofa J; Cohen EP; Tomic R; Xiang Q; Gore E
    Int J Radiat Oncol Biol Phys; 2012 Sep; 84(1):238-43. PubMed ID: 22300564
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Correlation of Radiation Pneumonitis History Before Nivolumab with Onset of Interstitial Lung Disease and Progression-free Survival of Patients with Pre-treated Advanced Non-small Cell Lung Cancer.
    Tamiya A; Tamiya M; Nakahama K; Taniguchi Y; Shiroyama T; Isa SI; Inoue T; Okishio K; Nishino K; Kumagai T; Suzuki H; Hirashima T; Imamura F; Atagi S
    Anticancer Res; 2017 Sep; 37(9):5199-5205. PubMed ID: 28870955
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Factors Associated With Efficacy and Nivolumab-Related Interstitial Pneumonia in Non-Small Cell Lung Cancer: A Retrospective Survey.
    Hata H; Mio T; Yamashita D; Matsumura C; Chisaki Y; Motohashi H; Yano Y
    Cancer Control; 2020; 27(4):1073274820977200. PubMed ID: 33297768
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Radiation Recall Pneumonitis Induced by Sintilimab: A Case Report and Literature Review.
    Wang M; Xu S; Zhu H
    Front Immunol; 2022; 13():823767. PubMed ID: 35280981
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Radiation recall pneumonitis induced by nivolumab in a patient with renal cell carcinoma.
    Nakamura K; Okubo K; Takahashi T; Mitsumori K; Ishigaki T; Ohnishi H
    IJU Case Rep; 2019 Jan; 2(1):30-33. PubMed ID: 32743367
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nivolumab and stereotactic radiation therapy for the treatment of patients with Stage IV non-small-cell lung cancer.
    Miyamoto S; Nomura R; Sato K; Awano N; Kuse N; Inomata M; Izumo T; Terada Y; Furuhata Y; Bae Y; Kunitoh H
    Jpn J Clin Oncol; 2019 Feb; 49(2):160-164. PubMed ID: 30452687
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Findings on Chest CT Performed in the Emergency Department in Patients Receiving Immune Checkpoint Inhibitor Therapy: Single-Institution 8-Year Experience in 136 Patients.
    Smith DA; Radzinsky E; Tirumani SH; Guler E; Petraszko A; Kikano E; Hoimes CJ; Ramaiya NH
    AJR Am J Roentgenol; 2021 Sep; 217(3):613-622. PubMed ID: 33295801
    [No Abstract]   [Full Text] [Related]  

  • 13. Characteristics, incidence, and risk factors of immune checkpoint inhibitor-related pneumonitis in patients with non-small cell lung cancer.
    Cho JY; Kim J; Lee JS; Kim YJ; Kim SH; Lee YJ; Cho YJ; Yoon HI; Lee JH; Lee CT; Park JS
    Lung Cancer; 2018 Nov; 125():150-156. PubMed ID: 30429014
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Relationship Between Prior Radiotherapy and Checkpoint-Inhibitor Pneumonitis in Patients With Advanced Non-Small-Cell Lung Cancer.
    Voong KR; Hazell SZ; Fu W; Hu C; Lin CT; Ding K; Suresh K; Hayman J; Hales RK; Alfaifi S; Marrone KA; Levy B; Hann CL; Ettinger DS; Feliciano JL; Peterson V; Kelly RJ; Brahmer JR; Forde PM; Naidoo J
    Clin Lung Cancer; 2019 Jul; 20(4):e470-e479. PubMed ID: 31031204
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pre-existing interstitial lung disease is associated with onset of nivolumab-induced pneumonitis in patients with solid tumors: a retrospective analysis.
    Yamaguchi T; Shimizu J; Hasegawa T; Horio Y; Inaba Y; Hanai N; Muro K; Hida T
    BMC Cancer; 2021 Aug; 21(1):924. PubMed ID: 34399710
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Radiation Versus Immune Checkpoint Inhibitor Associated Pneumonitis: Distinct Radiologic Morphologies.
    Chen X; Sheikh K; Nakajima E; Lin CT; Lee J; Hu C; Hales RK; Forde PM; Naidoo J; Voong KR
    Oncologist; 2021 Oct; 26(10):e1822-e1832. PubMed ID: 34251728
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pre-existing pulmonary fibrosis is a risk factor for anti-PD-1-related pneumonitis in patients with non-small cell lung cancer: A retrospective analysis.
    Yamaguchi T; Shimizu J; Hasegawa T; Horio Y; Inaba Y; Yatabe Y; Hida T
    Lung Cancer; 2018 Nov; 125():212-217. PubMed ID: 30429022
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Radiation recall pneumonitis triggered by an immune checkpoint inhibitor following re-irradiation in a lung cancer patient: a case report.
    Ye X; Yang J; Stebbing J; Peng L
    BMC Pulm Med; 2022 Feb; 22(1):54. PubMed ID: 35123465
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Incidence and risk factors for pneumonitis among patients with lung cancer who received immune checkpoint inhibitors after palliative thoracic radiotherapy.
    Saito S; Abe T; Iino M; Aoshika T; Ryuno Y; Ohta T; Igari M; Hirai R; Kumazaki Y; Yamaguchi O; Kaira K; Kagamu H; Noda SE; Kato S
    J Radiat Res; 2021 Jul; 62(4):669-675. PubMed ID: 34121123
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Potential benefits of volumetric modulated arc therapy to reduce the incidence of ≥ grade 2 radiation pneumonitis in radiotherapy for locally advanced non-small cell lung cancer patients.
    Imano N; Kimura T; Kawahara D; Nishioka R; Fukumoto W; Kawano R; Kubo K; Katsuta T; Takeuchi Y; Nishibuchi I; Murakami Y; Horimasu Y; Masuda T; Fujitaka K; Hattori N; Nagata Y
    Jpn J Clin Oncol; 2021 Dec; 51(12):1729-1735. PubMed ID: 34625805
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.